These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 26801080)

  • 1. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
    Hand E; Davis H; Kim T; Duhon B
    J Antimicrob Chemother; 2016 Apr; 71(4):1071-5. PubMed ID: 26801080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
    Junco SJ; Bowman MC; Turner RB
    Int J Antimicrob Agents; 2021 Aug; 58(2):106367. PubMed ID: 34058337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
    Ko JH; Kang CI; Cornejo-Juárez P; Yeh KM; Wang CH; Cho SY; Gözel MG; Kim SH; Hsueh PR; Sekiya N; Matsumura Y; Lee DG; Cho SY; Shiratori S; Kim YJ; Chung DR; Peck KR
    Clin Microbiol Infect; 2019 May; 25(5):546-554. PubMed ID: 30448331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial
    Hevia EC; Wooten L; Carr AL
    Ann Pharmacother; 2024 Jul; 58(7):698-704. PubMed ID: 37776160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients.
    Araoka H; Baba M; Okada C; Abe M; Kimura M; Yoneyama A
    Int J Infect Dis; 2017 May; 58():18-21. PubMed ID: 28257816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.
    Wang CH; Lin JC; Lin HA; Chang FY; Wang NC; Chiu SK; Lin TY; Yang YS; Kan LP; Yang CH; Chan MC; Yeh KM
    J Microbiol Immunol Infect; 2016 Jun; 49(3):378-86. PubMed ID: 25081988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Doxycycline or Minocycline to Sulfamethoxazole-Trimethoprim for Treatment of
    Alhayani T; Philpott CD; Liao S; Gentene AJ; Mueller EW
    Ann Pharmacother; 2024 Jan; 58(1):21-27. PubMed ID: 37125743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for hospital acquisition of trimethoprim-sulfamethoxazole resistant Stenotrophomonas maltophilia in adults: A matched case-control study.
    Wang CH; Lin JC; Chang FY; Yu CM; Lin WS; Yeh KM
    J Microbiol Immunol Infect; 2017 Oct; 50(5):646-652. PubMed ID: 28688829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
    Wei C; Ni W; Cai X; Zhao J; Cui J
    PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections.
    Tekçe YT; Erbay A; Cabadak H; Sen S
    J Chemother; 2012 Jun; 24(3):150-4. PubMed ID: 22759759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital.
    Duan Z; Qin J; Liu Y; Li C; Ying C
    BMC Microbiol; 2020 Sep; 20(1):294. PubMed ID: 32993493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
    Wang YL; Scipione MR; Dubrovskaya Y; Papadopoulos J
    Antimicrob Agents Chemother; 2014; 58(1):176-82. PubMed ID: 24145530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
    Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
    [No Abstract]   [Full Text] [Related]  

  • 14. Trimethoprim-sulfamethoxazole versus levofloxacin for the treatment of Stenotrophomonas maltophilia infections: A multicentre cohort study.
    Almangour TA; Alkherb Z; Alruwaite S; Alsahli R; Alali H; Almohaizeie A; Almuhisen S; Alowais SA; Saleh KB; Fetyani L; Alnashmi F; Alghofaily A; Abouobaid NI; Binkhamis KM; Tawfik EA; Alsowaida YS
    J Glob Antimicrob Resist; 2024 Sep; 38():42-48. PubMed ID: 38821443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections.
    Watson L; Esterly J; Jensen AO; Postelnick M; Aguirre A; McLaughlin M
    J Glob Antimicrob Resist; 2018 Mar; 12():104-106. PubMed ID: 28964955
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Flamm RK; Shortridge D; Castanheira M; Sader HS; Pfaller MA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Stenotrophomonas maltophilia Infections in Critically Ill Children.
    Tokatly Latzer I; Paret G; Rubinstein M; Keller N; Barkai G; Pessach IM
    Pediatr Infect Dis J; 2018 Oct; 37(10):981-986. PubMed ID: 29634621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antimicrobials on
    Santos Carvalhais BE; Souza E Silva C; Dos Santos KV
    Future Microbiol; 2021 Jan; 16(2):83-93. PubMed ID: 33470844
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.
    Nys C; Cherabuddi K; Venugopalan V; Klinker KP
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.